lead candid mavorixafor oral inhibitor possess proof concept
whim syndrom pivot develop whim syndrom expect begin
month trial mavorixafor scn wm also expect begin expect
creat long-term sharehold valu prove valu inhibit
therefor initi coverag outperform
lead asset mavorixafor oral small molecul antagonist
chemokin receptor wide express multifunct receptor
involv organogenesi hematopoiesi antimicrobi host defens
hematopoiet system bind ligand regul neutrophil releas
bone marrowand traffick senesc neutrophil back bone
marrow clearanc overstimul pathway lead retent
neutrophil bone marrow myelokathexi neutropenia peripheri
mavorixafor first indic wart hypogammaglobulinemia infect
mutat result constitut activ open-label phase ii
dose escal trial mavorixafor demonstr proof-of-concept whim syndrom
includ elimin sever neutropenia regress wart phase trial
whim syndrom expect begin quarter report data manag
believ whim patient poc in-hand view develop
rel low risk believ whim syndrom support global sale
also plan initi phase i/ii trial mavorixafor sever congenit neutropenia
scn waldenstrom macroglobulinemia wm data scn trial
anticip data wm trial schedul releas
whim like mutat found wm patient predict poor outcom
ibrutinib believ mavorixafor like provid benefit patient anticip
wm could support global sale mavorixafor npv analysi whim
wm indic share worth repres upsid
pleas see page report import disclosur
clinical-stag biopharmaceut compani focus develop
therapeut treatment rare diseas lead asset mavorixafor oral small
molecul antagonist chemokin receptor mavorixafor first indic whim
syndrom rare autosom domin immunodefici caus mutat
result constitut activ open-label phase ii dose-escal trial
mavorixafor demonstr proof-of-concept phase trial expect report
data believ whim syndrom support global sale also
plan initi phase i/ii trial mavorixafor sever congenit neutropenia scn
waldenstrom macroglobulinemia wm anticip wm could support
global sale mavorixafor believ share outperform compani
demonstr valu inhibit whim syndrom wm indic
initi phase trial scn
initi phase i/ii waldenstrom
mavorixafor gener whim
mavorixafor gener wm
mavorixafor maintain exclus
mavorixafor gener
sale within whim wm
mavorixafor success develop
one second-gener
whim syndrom less preval
expect sale disappoint
mavorixafor success develop
wm indic
mavorixafor ip prove weaker
develop small molecul antagonist treatment rare diseas
cancer wide express multifunct receptor involv
organogenesi hematopoiesi antimicrobi host defens immun cell
recognit ligand regul neutrophil releas bone marrow
traffick senesc neutrophil back bone marrow clearanc lead
candid mavorixifor produc proof-of-concept wart hypogammaglobulinemia
infect myelokathexi whim syndrom phase data anticip
plan initi phase i/ii trial mavorixafor sever congenit neutropenia scn
waldenstrom macroglobulinemia wm
sever congenit neutropenia scn famili orphan genet disord
inherit de novo mutat caus impair neutrophil differenti matur
traffick and/or kill capac form neutropenia scn associ
increas risk sever infect wart hypogammaglobulinemia infect
myelokathexi whim syndrom scn caus activ mutat
chemokin receptor import neutrophil immun cell
traffick lead candid oral inhibitor mavorixafor
design modul signal therebi drive neutrophil exit bone
marrow control infect
phase ii data mavorixafor whim patient well academ data anoth
inhibitor plerixafor establish proof-of-concept inhibit
whim syndrom mavorixafor placebo control pivot trial expect begin
primari endpoint time neutrophil threshold hour data
expect academ literatur indic whim syndrom extrem rare
patient consult earli market research indic
significantli underdiagnos believ whim popul could
patient view clinic develop whim rel low risk believ
mavorixafor could gener global whim sale manag project
whim preval prove correct
consult believ mavorixafor may also activ addit scn non-
inherit neutropenia myelodysplast syndrom md -associ
neutropenia disclos plan initi phase ii trial non-
whim scn initi data report
whim-lik mutat also found within malign cell clone waldenstrom
macroglobulinemia wm patient laboratori studi demonstr
whim-lik mutat increas prolifer wm clone furthermor clinic data
pre- post-ibrutinib era indic whim patient
inferior deep respons rate long-term outcom consequ
consult believ inhibit could improv outcom wm patient rel
current standard care ibrutinib-bas regimen phase ii trial
mavorixafor ibrutinib wm expect start report initi data
believ wm market support global
complet revers merger march follow
success merger execut offer manag anticip
provid suffici resourc fund compani end includ
gener pivot data whim syndrom well proof-of-concept dataset
scn wm npv analysi assum mavorixafor success develop
whim wm includ discount rate analysi indic share
worth fulli dilut basi ev share
current trade would repres upsid today valuat
addit upsid could provid success declar indic scn
potenti indic identifi consult md therefor
initi coverag outperform rate
initi phase trial scn
initi phase i/ii waldenstrom
submit ind
top-lin result phase scn
updat data phase ii ole whim
result phase i/ii waldenstrom
top-lin result phase whim
compani report cowen compani
cowen compani
financi year growth sale sale total free year growth valu termin valu net dilut share per fulli dilut valu calcul cowen
cowen compani
cowen compani
rate incom incom incomeoth rate incom incom cowen
clinical-stag biopharmaceut compani focus develop therapeut
treatment rare diseas includ primari immunodefici certain
type cancer lead asset mavorixafor oral small
molecul antagonist chemokin receptor wide express
multifunct receptor involv organogenesi hematopoiesi antimicrobi
host defens hematopoiet system bind ligand
regul neutrophil releas bone marrowand traffick senesc
neutrophil back bone marrow clearanc overstimul
pathway lead retent neutrophil bone marrow
myelokathexi neutropenia peripheri mavorixafor first indic wart
hypogammaglobulinemia infect myelokathexi whim syndrom rare
autosom domin immunodefici disord caus mutat
result constitut activ open-label phase ii dose escal trial
mavorixafor demonstr proof-of-concept whim syndrom phase trial
expect report data believ whim syndrom support
global sale also plan initi phase i/ii trial mavorixafor sever congenit
neutropenia scn waldenstrom macroglobulinemia wm data
scn trial anticip data wm set releas
anticip wm could support global sale mavorixafor
therefor believ share outperform compani demonstr
valu inhibit whim syndrom wm indic
wide express multifunct receptor involv organogenesi
hematopoiesi antimicrobi host defens immun cell recognit
ligand regul neutrophil releas bone marrowand
traffick senesc neutrophil back bone marrow clearanc one site
particularli high express bone marrow constitut
express stromal cell bone marrow signal care
balanc retain differenti lymphocyt allow releas upon full
maturationor respons exogen signal infect requir flood
lymphocyt releas
primari immunodefici immun system disord lead increas
suscept infect cancer whim syndrom classifi type sever
congenit neutropenia scn famili primari immunodefici lead
danger low level neutrophil whim syndrom diagnos symptom
wart hypogammaglobulinemia infect myelokathexi whim
whim syndrom associ famili nine mutat c-terminu
nine mutat believ caus prevent
normal intern bind result remain
activ cell surfac caus lymphocyt retent bone marrow
myelokathexi sever neutropenia peripher blood
overactiv seen whim syndrom may also make cell suscept
apoptosi reduc cell output thymu contribut restrict t-cell
repertoir reduc cell popul
system immun defici found whim patient lead poorli control
human papilloma viru hpv infect associ hallmark symptom sever
wart burden whim patient also increas suscept mani non-hpv
infect virally-driven cancer interestingli whim patient abl
mount effect acut respons vaccin durabl respons poor
result poorli control hpv infect whim patient tend develop visibl
wart hand feet age genit wart
begin initi sexual activ wart particularli persist
surgeri cryotherapi fulgur ineffect importantli hpv infect
also transform cancer cervic head neck anal penil therefor
presenc poorli control hpv infect believ significantli increas risk
hpv-driven tumor whim patient
healthi subject hpv vaccin shown significantli reduc risk
hpv infect hpv-associ cancer unfortun whim patient
antibodi respons vaccin transient one studi whim patient protect
titer absent one year vaccin thu protect effect hpv
vaccin whim patient short-liv best
whim patient suscept hpv infect thought primarili due lack
suffici cell activ cell respons limit hpv pathogenesi
tumorigenesi circul level typic low whim patient
driven whim patient reduc tcr repertoir impair cell
activ final plasmacytoid dendrit cell may also respons wart
regress cell also regul reduc whim patient
anecdot clinic evid suggest address underli immun defici
prompt wart lesion regress evid consist case report demonstr
lesion respond immun stimulatori treatment patient
spontan lost whim allel myeloid compart clear wart
lesion respond administr drug altogeth
find suggest correct hematolog defect whim may provid
signific benefit patient reduc wart burden cancer risk
mani whim patient unabl mount suffici humor immun respons
vaccin infect thought caus reduc circul level
immatur cell disrupt cell stimul lymph node poor mainten
memori cell bone marrowal regul part
result whim patient low level circul immunoglobulin igg
immunoglobulin igm and/or immunoglobulin iga hypogammaglobulinemia
well establish risk factor sever infect
sever neutropenia reduc circul cell count divers poor humor
immun combin make whim patient suscept infect recurr ear
infect begin childhood result tympan membran ruptur
scar later life whim patient often develop recurr acut sinus
recurr lung infect caus bronchiolar damag bronchiectasi
pulmonari dysfunct death addit dental caviti gingiv
periodont may lead poor dentit tooth loss skin immun also
compromis skin soft tissu infect caus recurr cellul abscess
deep tissu infect final whim patient increas risk develop
myelokathexi describ condit sever neutropenia retent
matur apoptot neutrophil bone marrow thought result
excess signal neutrophil delay releas bone
marrow period acut infect whim patient neutrophil count normal
respons epinephrin temper sever infect find indic
whim patient neutrophil remain respons modest modif
signal milieu importantli chronic neutropenia view clinic meaning
endpoint global regul
absenc fda-approv therapi specif indic whim syndrom
patient current treat therapi indic broader indic
sever congenit neutropenia scn treatment approach non-specif
safeti efficaci determin whim-specif clinic trial
patient typic receiv intraven ig ivig replac g-csf treatment
improv hypogammaglobulinemia neutropenia howev ivig inconveni due
need repeat inject g-csf use limit short half-lif
hour rout administr subcutan side effect profil anemia
sever thrombocytopenia high dose particularli sever bone pain whim
patient heighten risk malign long-term use addit g-csf
affect cytopenia neutropenia monocytopenia
lymphopenia hypogammaglobulinemia remain thu even treatment
patient continu experi recurr infect wart mavorixafor on-going
phase ii trial enrol patient previous receiv ivig g-csf steroid and/or
plerixafor commerci avail iv inhibitor despit treatment
experienc sever infect six month prior enrol
date cure report four whim patient three receiv
allogen hematopoiet stem cell transplant fourth patient experienc
spontan chromothripsi led restor wild type importantli
hsct restor humor immun peripher blood count well neutrophil
lead candid mavorixafor oral administ
inhibitor believ defect signal whim-mut correct
partial inhibit regardless mutat expect
improv neutrophil count long-term clinic outcom earli data
mavorixafor indic drug capabl safe increas neutrophil count
whim patient pivot trial expect begin believ mavorixafor
could launch achiev ww sale whim
mavorixafor treatment approach valid clinic trial use fda-
approv antagonist mozobil plerixafor sanofi mozobil inject
antagonist approv use hematopoiet stem cell mobil prior autolog
transplant patient non-hodgkin lymphoma multipl myeloma
short-term phase dose-escal studi plerixafor one nation institut
nih nine patient total demonstr drug could safe mobil
neutrophil also leukocyt follow-up phase studi also
conduct nih plerixafor mg/kg/day found increas
circul neutrophil lymphocyt monocyt count six month three
patient whim syndrom demonstr hematopoiet effect
durabl importantli hematopoiet improv translat clinic benefit
frequenc infect also reduc rel baselin rate infect
three year preced studi enrol one-year follow-up
treatment cessat significantli chang infect rate observ despit
fact two patient take g-csf comparison time period
new wart occur patient receiv plerixafor sever exist wart
improv resolv dose-limit toxic note
subsequ random double-blind phase trial g-csf vs plerixafor
initi on-going recruit process three
whim patient identifi advanc diseas werent candid g-
csf make inelig studi patient enrol open-label
trial plerixafor dose accord phase protocol result month
treatment publish new england journal medicin januari
six month plerixafor treatment first patient experienc resolut
lower-leg skin lesion includ prurit follicul ulcer chronic
decreas hpv strain detect prior treatment becam
undetect therapi persist peritibi mass remov surgic
complet heal wound ambul improv minut
walk pre-treat high-intens soccer hike post-treat patient
reduct infect frequenc alongsid persist mandibular osteomyel
fistula develop oper perform bone graft skin flap
fail despit lack neutropenia patient die week post-surgeri
multidrug-resist ventilator-associ pneumonia sepsi patient
reduct infect frequenc importantli patient respons plerixafor vari
lymphocyt notabl nave memori cell respons
patient neutrophil respons patient potenti
confound result studi fact addit plerixafor
review scientif literatur indic exact mechan mozobil-
induc leukocyt mobil topic on-going debat mozobil may block
leukocyt retent bone marrow immun organ
neutrophil retent lung and/or home circul leukocyt
bone marrow consult agre multipl mechan could
contribut mozobil neutrophil-boost activ confid
degre neutrophil increas could achiev reduc
retent bone marrow
mavorixafor oral alloster antagonist origin develop
genzym oral once-daili inhibitor potenti provid
conveni dose improv patient complianc chronic use rel mozobil
plerixafor mavorixafor spun genzyme/sanofi
pharmaceut goal further develop oncolog rare
diseas though mozobil mavorixafor bind compound
structur overlap bind differ site receptor
mavorixafor demonstr proof-of-concept open-label dose escal phase
ii trial patient whim syndrom phase ii trial mavorixafor
administ start daili dose increas daili eight
adult patient neutropenia anc and/or lymphopenia alc
genet confirm mutat enrol patient recent
receiv plerixafor treatment month g-csf/gm-csf immunoglobulin
week elig enrol primari object trial demonstr
safeti pharmacokinet pharmacodynam addit blood count
neutrophil measur goal increas daili absolut neutrophil count
anc absolut lymphocyt count alc threshold hour anc
threshold initi pre-specifi alc threshold pre-specifi
cutoff base nation cancer institut advers event
grade system classifi anc sever life threaten
alc within rang healthi individu importantli anc
healthi peopl could prompt hospit whim patient typic
neutrophil count approxim without life-threaten infect
primari endpoint later modifi anc threshold interest
avoid possibl result reflect regress mean
baselin enrol patient anc cells/l neutrophil count
vacil within rang throughout day base physic activ diurnal
variat first two patient enrol began treatment mavorixafor
qd dose deem sub-optimal subsequ patient began qd
week patient underw area-under-the-curv auc
measur anc alc dose escal occur aucanc cell hr/l
interim result first five patient present american societi
hematolog meet decemb time data cutoff octob
two patient treat nine month two patient
treat four month fifth patient histori psoriasi
discontinu due grade rash develop five day initi treatment
treatment-rel dri mouth nausea two dri eye nasal dryness
dyspepsia conjunct rash one grade except
cholecyst grade requir gall bladder remov consid treatment-
relat patient experienc dose-depend increas anc alc
baselin measur alc increas anc notabl patient
experienc abnorm elev anc attribut
sub-clin infect drive neutrophil releas bone marrow patient
develop one small new wart week patient dose qd
updat interim result present poster eha poster extend
follow-up time five month data cutoff march patient
remain studi includ initi data three addit patient patient
treat month three patient studi includ
previous report patient discontinu day one patient treat
five month two patient treat one month
time data cutoff seven patient undergon anc
measur drug four week dose daili
though subject began drug differ start dose manag
indic drug achiev steadi state within approxim day
subject reach steadi state dose time measur
patient three patient aucanc measur threshold
four patient aucanc measur threshold three
threshold dose increas daili anc
reassess three patient two patient achiev anc threshold
increas dose notabl patient receiv prophylact inhal
system antibiot therapi studi may artifici elev
anc measur addit patient undergon splenectomi
known increas total leucocyt count
anc reassess patient one month later
aucanc measur threshold thu across seven evalu patient five
met aucanc threshold signifi clinically-meaning increas anc
addit six seven met aucalc threshold signifi clinically-
meaning increas alc sinc decid move forward primari
endpoint time threshold threshold report
measur phase ii result date appear even stronger even without includ
patient
addit improv lab valu patient report fewer infect one
patient histori untreat sever wart lesion experienc reduct
wart lesion report mavorixafor associ treatment-
relat seriou advers event well toler daili dose
day treatment emerg event began worsen
first dose mavorixafor occur one patient sinus dri
mouth nausea two mavorixafor-rel nausea dri eye
dri mouth nasal dryness dyspepsia conjunct rash one relat
grade patient discontinu studi develop rash day
follow mg mavorixafor treatment patient continu receiv
mavorixafor on-going phase ii open-label extens studi
beyond safeti data collect eight whim patient dose mavorixafor
date insight safeti inhibit come mozobil earli
clinic trial mozobil initi studi inhibitor hiv viru replic
set mozobil use higher dose achiev complet inhibit
dose chronic earli clinic trial mozobil administ iv dose
g/kg/h hiv-infect patient dose-rel trend
gastrointestin disord mostli sens abdomin full loos stool
patient low-dos group g/kg/h patient
high dose group g/kg/h experienc symptom patient
receiv g/kg/h experienc paresthesia perior extrem
appear dose-rel one patient seriou possibl drug-rel
thrombocytopenia dose g/kg/h two patient unexpect prematur
ventricular contract seriou dose respect
final orthostat chang one episod ventricular ectopi also occur
consid unexplain due poor efficaci ae profil
develop mozobil hiv ultim abandon
mozobil subsequ studi combin g-csf mobil hsc
patient non-hodgkin lymphoma nhl multipl myeloma mm prior
undergo transplant advers event occur least patient
receiv mozobil frequent control group g-csf alon
mobil apheresi includ gastrointestin issu
diarrhea nausea inject site reaction erythema hematoma
irrit etc fatigu mozobil ultim approv fda use
set dose day
importantli symptom inhibit appear improv signal
partial inhibitedth treatment goal whim syndrom nih-fund trial
plerixafor whim dose rang g/kg/day g/kg/day
mobil dose equival approxim g/kg/hour given iv
 hiv dose mavorixafor oral dose meant produc
compar level inhibit thu expect mavorixafor safety/toler
profil remain accept
base phase ii whim data convers fda plan initi
phase clinic trial mavorixafor qd whim trial enrol whim
patient random mavorixafor placebo week primari
endpoint time threshold tat neutrophil count hour
analysi conduct week timepoint secondari endpoint includ infect
rate assess wart burden phase whim trial expect begin
report top-lin data
phase trial consult look neutrophil count consist
though one note would even ideal
consult believ neutrophil whim patient fulli function releas
bone marrow well establish extent neutropenia directli
correl infecti risk therefor consult indic
improv neutropenia within whim patient translat clinic
improv beyond neutrophil count consult would also view
improv leukocyt count posit result importantli current soc g-
csf impact leukocyt count
meanwhil nih-fund double-blind random phase trial plerixafor
whim complet enrol data expect trial enrol
subject random receiv g-csf plerixafor one year use crossov
design dose determin patient individu neutrophil respons stabl
background medic antibiot and/or immunoglobulin allow primari
endpoint comparison sever infect score g-csf
plerixafor month studi drug secondari endpoint includ
compon infect antibiot use fever day work control wart
long-term safeti symptom chronic infect drug toler patient
prefer increas leucocyt level qualiti life score expect data
valid impact inhibit clinic outcom whim
patient pharamaceut note unclear quickli immun system
whim patient return pre-treat statu therefor manag believ
trial crossov design could report impact inhibit
incid whim syndrom well defin publish estim put
incid whim one million live birth patient
howev estim diseas incid limit rariti diseas
incomplet penetr characterist sign symptom lack wart
second decad life absenc neutropenia whim patient undergo
acut infect nih recruit patient whim cohort clinic june
total case report literatur rariti
diseas mean physician present case worsen
chanc make proper diagnosi whim patient present
addit one-third whim case aris de novo parent test neg
whim patient rare case present characterist
symptom final given myelokathexi determin direct bone
invas costli procedur unlik chang recommend treatment
protocol therefor consult believ literatur estim like
conserv base upon experi diagnos whim patient believ
literatur like least furthermor
conduct preliminari market research indic fact
whim patient
aid physician awar diagnosi whim syndrom partner
patient foundat registri includ jeffrey model foundat univers
washington immun defici foundat hopitaux universitair estimate parisien
trousseau la roche-guyon patient prospect screen studi initi
april collabor jeffrey model foundat goal trial
establish systemat diagnost approach whim syndrom medic scienc
liaison also deploy run diseas educ awar
octob receiv orphan drug design fda
mavorixafor treatment whim syndrom mavorixafor competit
matter patent expect expir decemb without patent extens
could add five year addit patent applic file
grant would provid addit protect mavorixafor also
expect benefit new chemic entiti orphan drug exclus
consult report treat whim g-csf improv neutropenia
noth wartsand associ risk progress aml given
mavorixafor abil address issu oral dose consult
expect physician jump opportun use drug also unclear
sanofi conduct toxic studi would requir order support
fda approv indic whim chronic dose plerixafor would
requir sanofi pursu label would expect plerixafor price
per vial uncertain safeti profil would prevent off-label use addit expect
patient would strong prefer oral qd drug mavorixafor versu bid
inject plerixafor therefor competit plerixafor expect minim
model whim preval
diagnos expect patient outreach/identif program increas
diagnosi rate estim mavorixafor launch
late achiev penetr among diagnos whim patient
net price in-lin mani orphan drug therefor
model peak sale within whim syndrom anticip greater
central scn treatment europ support higher whim diagnosi rate
similar penetr diagnos popul net price
 price lead peak european sale estim therefor
model global peak sale mavorixafor whim syndrom
cowen compani
sever congenit neutropenia scn famili disord includ whim share
hallmark symptom sever neutropenia scn caus known
mutat mutat lead varieti neutrophil defect includ poor
differenti increas apoptosi abnorm traffick believ
central role retent neutrophil bone marrow allow mavorixafor
efficaci mani neutropenia consult agre mavorixafor
mechan like activ least scn particularli
interest pursu inhibit scn like whim
defici lead sever cytopenia patient also develop signific wart
burden across mutat scn estim preval approxim
 eu therefor could repres signific label
plan initi phase trial mavorixafor scn initi data
anticip importantli patient enrol trial without
prior genet identif scn screen potenti mutat
allow identifi pattern treatment efficacy/failur design
appropri registr enabl trial data warrant
mavorixafor third indic waldenstrom macroglobulinemia wm rare
incur form non-hodgkin lymphoma wm character accumul
malign lymphoplasmacyt cell bone marrow lymph node spleen
addit excess product serum igm diseas indol typic begin
asymptomat monoclon gammopathi undetermin signific mgu
natur histori studi wm conduct median surviv
follow diagnosi wm year main caus death includ
diseas progress transform high-grad lymphoma complic
therapi reduct igm may improv surviv given presenc excess
monoclon igm protein result hyperviscos syndrom peripher neuropathi
hemolyt anemia immun complex vascul
 whim whim diagnos whim penetr whim patient util price revenu whim syndrom growth y/i whim markettot whim diagnos whim penetr whim patient util price revenu whim syndrom growth y/i wm patient ww revenu whim syndrom growth y/i cowen
wm estim preval eu annual incid
 eu approxim one-quart wm
patient asymptomat smolder time diagnosi patient
good prognosi without therapi year surviv rate approxim
normal popul treatment typic begun patient develop
symptom fever/night sweat splenomegali hemoglobin platelet
count coexist diseas al amyloidosi
cure goal treatment control symptom prevent tissu damag
histor patient receiv rituximab monotherapi combin
chemotherapi although ibrutinib /- rituximab increasingli becom standard
care approxim half wm patient experi igm flare upon initi
rituximab consult estim wm patient symptom
requir treatment nearli treat patient receiv ibrutinib-bas
regimen adopt ibrutinib monotherapi particularli strong within elderli
patient high igm baselin order avoid igm flare highest
risk complic
given involv develop hematopoet cell unsurpris
also involv hematopoet malign whole genom sequenc
wm uncov mutat evalu waldenstrom
macroglobulinemia patient somat mutat nonsens
frameshift mutat resembl nonsens frameshift germlin
mutat found whim
preclin research suggest mutat activ
waldenstrom lead increas cell prolifer mous model paper
publish blood mice inject cell saw increas dissemin
tumor cell rel mice inject wild type waldenstrom cell
addit presenc waldenstrom bone marrow mesenchym
stem cell cell show increas adhes cell prolifer
vitro final gene relat tumor invas prolifer anti-apoptosi
oncogenesi enrich cxcr- mutat cell rel wild type
preclin research also suggest waldenstrom patient whim-lik
mutat resist treatment ibrutinib specif studi
demonstr somat mutat promot ibrutinib resist
activ akt erk signal
clinic research confirm wm patient mutat less like
respond ibrutinib monotherapi phase ii trial ibrutinib patient wm
fewer patient respond therapi rel
patient vs vgpr vgpr believ earli indic
efficaci wm use proxi long-term rate given slow
progress diseas wm mean signific differ efficaci measur
may note sever year treatment initi
ibrutinib efficaci wm mutat statu
outcom mutat patient also rel poor patient util
rituximab monotherapi vgpr rate combin ibrutinib
consult also note statu well-establish prognost factor
relaps within year wm poor outcom standard monotherapi
addit doublet regimen prompt physician administ three-drug
combin rituxan ibrutinib chemotherapi first line regimen wm
patient mutant patient also high risk progress
relaps year consult believ drug capabl
doubl vgpr rel btk monotherapi would approvableand provid
clinic meaning benefit wm patient suggest vgpr rang
innov trial combin ibrutinib rituximab produc vgpr
median follow-up time month gain commerci traction believ
mavorixafor ibrutinib beat bar vgpr
plan initi phase i/ii trial mavorixafor wm phase data
anticip trial enrol patient mutat
fail prior treatment regimen lack ibrutinib enrol patient
receiv mavorixafor combin ibrutinib dose escal combin
expans endpoint includ safeti pk/pd vgpr cr rate
consult believ drug capabl get patient asymptomat
state quickli drive deeper respons well toler would
meaning improv wm patient mani signific
symptom high level igm fragil state due advanc
age physician note drug appear fairli non-tox
therefor would fit profil efficaci demonstr term efficaci
consult would like see doubl deep respons rate vgpr cr
would note base upon fda feedback beigen pursu global pivot trial
wm compar vgpr cr rate zanubrutinib vs ibrutinib therefor deep
respons rate appear viabl approv pathway
bistol-my squibb develop antibodi ulocuplumab treatment
waldenstrom combin ibrutinib phase i/ii trial initi
octob dana-farb cancer institut set complet
phase dose-escal portion trial enrol wm
patient ibrutinib-nav receiv ibrutinib oral daili ulocuplumab
iv time per cycl cycl primari endpoint determin
maximum dose maximum toler dose base number dose-limit
toxic cohort one year major respons rate pr vgpr cr two
year view ulocuplumab less attract profil due difficulti
precis regul extent inhibit intraven rout
seer databas indic approxim non-hodgkin lymphoma
patient patholog confirm wm patient
non-hodgkin lymphoma suggest wm preval approxim
consult estim approxim half patient asymptomat
thu requir therapi symptomat estim
approxim mutat base articl publish blood
consult estim approxim symptomat patient receiv
model mavorixafor label expand includ broad indic
symptomat wm patient project mavorixafor eventu captur
elig patient popul price pariti whim wm would
lead peak global sale wm
cowen compani
though take target approach mavorixafor develop consult
note drug potenti use wide hematolog
indic involv neutropenia one consult note myelodysplast syndrom
would particularli well suit treatment inhibitor given md
patient frequent neutropenia neutropenia often associ
abnorm high level indic excess signal could
drive md associ neutropenia importantli fda approv treatment
treatment neutropenia md patient cancer databas indic
approxim case myelodysplast syndrom diagnos
annual mavorixafor develop indic even modest
penetr could gener peak sale anoth consult didnt see
mavorixafor couldnt use off-label treatment nearli neutropenia
overexpress detect differ cancer includ non-
hematopoet malign pre-clin research suggest hypox condit
tumor progress may promot express factor
 wm patient symptomat wm patient patient patient receiv ibrutinib-bas wm patient receiv ibrutinib-bas penetr wm patient util price per patient revenu front line wm annual growth wm marketwm patient symptomat wm patient patient patient receiv ibrunitib-bas wm patient receiv ibrutinib-bas penetr wm patient util price per patient revenu wm annual growth wm patient revenu wm growth y/i cowen
shown increas express specif tumor type renal cell
carcinoma breast cancer prostat cancer
report interim data phase ib melanoma trial mavorixafor
monotherapi associ meaning increas cell also
assess mavorixafor phase iia open-label trial clear cell renal cell carcinoma
ccrcc combin tyrosin kinas inhibitor axitinib primari endpoint
assess mpf aim beat benchmark set axitinib patient
immedi prior tki mpf month trial yet reach mpf studi
subject trial year last patient enrol februari
data expect posit plan pursu collabor larger
biopharmaceut compani futur develop potenti commerci
mavorixafor immune-oncolog indic
develop antagonist thought penetr blood-
brain barrier may allow drug treat brain cancer includ glioblastoma
multiform gbm final develop second-gener molecul
design improv patient complianc eas use program
preclin develop disclos timelin move either clinic
calcul target price employ one valuat methodolog
includ discount earn analysi discount cash flow analysi net present
valu analysi and/or compar compani analysi analys may may
requir use object measur price-to-earn price-to-sal multipl
well subject measur discount rate
make invest recommend earli stage pre-commerci biotechnolog
compani base upon assess technolog probabl pipelin
success potenti market opportun event success howev
compani lack tradit financi metric believ good
methodolog assign specif target price stock
multipl risk inher invest biotechnolog sector
beyond system risk also clinic regulatori commerci risk addit
biotechnolog compani requir signific amount capit order develop
clinic program capital-rais environ alway chang risk
necessari capit complet develop may readili avail
unprofit approv product like rais
addit capit public market prior turn profit limit clinic
trial experi lead candid mavorixafor moreov mavorixafor face number
clinic regulatori commerci hurdl prior becom success project
futur sale mavorixafor inher difficult
make invest recommend earli stage pre-commerci biotechnolog
compani base upon assess technolog probabl pipelin
success potenti market opportun event success howev
compani lack tradit financi metric believ good
methodolog assign specif target price stock
